<DOC>
	<DOCNO>NCT02273362</DOCNO>
	<brief_summary>This pilot clinical trial study best dose erlotinib hydrochloride see well work prevent liver cancer patient scar ( cirrhosis ) liver undergoing surgery . Erlotinib hydrochloride may help inhibit development fibrous tissue prevent liver cancer form patient cirrhosis liver .</brief_summary>
	<brief_title>Erlotinib Hydrochloride Preventing Liver Cancer Patients With Cirrhosis Liver Undergoing Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine safe minimum effective dose ( MED ) daily erlotinib ( erlotinib hydrochloride ) inhibit epidermal growth factor receptor ( EGFR ) signal target organ ( liver ) assess phosphorylated ( phospho ) -EGFR stain . SECONDARY OBJECTIVES : I . Determine relationship erlotinib dose-schedule side effect participant cirrhosis . TERTIARY OBJECTIVES : I . Determine relationship erlotinib dose-schedule immuno-histochemical staining pattern phospho-ERK , proliferate cell nuclear antigen ( PCNA ) , epidermal growth factor ( EGF ) , alpha smooth muscle actin ( alphaSMA ) liver . II . Determine relationship erlotinib dose-schedule gene expression signature associate prognosis cirrhosis participant follow hepatocellular carcinoma ( HCC ) resection . III . Determine relationship erlotinib dose-schedule viral load participant hepatitis C virus ( HCV ) positive ( + ) . IV . Determine relationship erlotinib dose-schedule erlotinib plasma level day liver resection . OUTLINE : This dose-escalation study . Patients receive erlotinib hydrochloride orally ( PO ) daily ( QD ) 7 day ( depend date surgery , treatment range may 5-14 day ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>PREREGISTRATION INCLUSION : Individuals clinical diagnosis fibrosis cirrhosis liver ( ChildPugh classification A ; ChildPughTurcotte score 6 less ) : An indication surgical liver resection , OR A clinical liver biopsy ( research tissue specimens available analysis ) = &lt; 3 month prior preregistration Willingness discontinue smoke study two week prior begin study willingness smoke take study medication Not pregnant breast feeding ; woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform study physician immediately Willingness use adequate contraception avoid pregnancy impregnation 2 week discontinue study agent Willingness provide mandatory blood specimen Able undergo : Percutaneous transjugular biopsy cirrhotic liver least 7 day prior liver resection ( surgical cohort ) , OR A biopsy cirrhotic liver ( nonsurgical cohort ) Willingness authorize collection tissue surgicallyresected liver clinical liver biopsy analyse Ability understand willingness sign write informed consent document REGISTRATION INCLUSION : Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 International normalize ratio ( INR ) = &lt; 1.5 Platelets &gt; = 50 B/L ( 10^9/L ) Total bilirubin = &lt; 3 × institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 5 × institutional ULN Creatinine = &lt; 1.5 × institutional ULN Nonsurgical cohort : positive phosphoEGFR assessment ( &gt; = 100 stain pixel ) tissue obtain previous clinical liver biopsy Preintervention biopsy sample collect PREREGISTRATION EXCLUSION : Any prior treatment erlotinib agent whose primary mechanism action know inhibit EGFR Participants know diagnosis human immunodeficiency virus ( HIV ) ; Note : HIV screen test perform evaluate criterion Participants regularly ( &gt; = 2 time per week ) use drug alter pH gastrointestinal ( GI ) tract , proton pump inhibitor ( PPI ) antacid ; exception : individual use prescription PPIs approval primary health care provider discontinue duration clinical trial participation may enrol ; alternate drug control gastroesophageal reflux disease ( GERD ) /peptic ulcer disease ( PUD ) symptom suggest Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , psychiatric illness/social situation would limit compliance study requirement Use potent CYP3A4 inhibitor , ketoconazole , atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , troleandomycin , voriconazole , grapefruit grapefruit juice Use CYP3A4 inducer rifampicin , rifabutin , rifapentine , phenytoin , carbamazepine , phenobarbital , St. John 's wort History allergic reaction attribute compound similar chemical biologic composition erlotinib ( Tarceva ) Participants warfarin , Lovenox , Plavix , comparable medication hold percutaneous transjugular liver biopsy surgery indicate Nonsurgical cohort : pathology report clinical liver biopsy ( = &lt; 3 month prior preregistration ) demonstrate histologic abnormality associate chronic hepatitis , steatohepatitis , fibrosis , cirrhosis REGISTRATION EXCLUSION : Receiving investigational agent = &lt; 6 month prior registration Surgical cohort ( cohort A ) : percutaneous transjugular biopsy incomplete perform</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>